|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT00551343 |
|
Date of registration:
|
29/10/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
|
|
Scientific title:
|
Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome. |
|
Date of first enrolment:
|
October 2007 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00551343 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Australia
| | | | | | | |
|
Contacts
|
|
Name:
|
Lesley V Campbell, Prof |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Garvan Institute of Medical Research |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- see below
Exclusion Criteria:
- Diabetes mellitus, acute infections
Age minimum:
18 Years
Age maximum:
45 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Prader-Willi Syndrome
|
|
Intervention(s)
|
|
Drug: Exenatide
|
|
Primary Outcome(s)
|
|
satiety hormones
[Time Frame: 1 day]
|
|
Secondary Outcome(s)
|
|
appetite (visual analogue scale) insulin secretion
[Time Frame: 1 day]
|
|
Secondary ID(s)
|
|
X07-0178
|
|
H07/045
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|